Clinical Research Directory
Browse clinical research sites, groups, and studies.
Comparison of Different Dose of Anti-T Lymphocyte Globulin (ATLG) in Haploidentical HSCT for GVHD Prophylaxis
Sponsor: Institute of Hematology & Blood Diseases Hospital, China
Summary
This study aims to compare the incidence of graft-versus-host disease (GVHD) in haploidentical hematopoietic stem cell transplant recipients who receive varying doses of anti-T lymphocyte globulin (ATLG) for GVHD prophylaxis. Our primary objective is to determine the optimal dose of ATLG for preventing acute GVHD (aGVHD). Additionally, we plan to evaluate the impact of different doses of ATLG on post-transplant viral infections and other clinical outcomes.
Official title: Dose Study of Anti-T Lymphocyte Globulin (ATLG) in GVHD Prophylaxis
Key Details
Gender
All
Age Range
16 Years - 65 Years
Study Type
INTERVENTIONAL
Enrollment
104
Start Date
2024-07-31
Completion Date
2026-07-31
Last Updated
2024-07-29
Healthy Volunteers
No
Conditions
Interventions
ATLG
5 mg/kg/day IV for 4 consecutive days (day-5 to -2 before transplantation). All transplant recipients will receive myeloablative conditioning or modified myoloablative conditioning and standard GVHD prophylaxis.
ATLG
7.5mg/kg/day IV for 4 consecutive days (day-5 to -2 before transplantation). All transplant recipients will receive myeloablative conditioning or modified myoloablative conditioning and standard GVHD prophylaxis.
Locations (5)
The Southwest Hospital of Amu
Chongqing, Chongqing Municipality, China
Fujian Medical University Union Hospital
Fuzhou, Fujian, China
The First Bethune Hospital of Jilin University
Jilin, Jilin, China
Tai'an City Central Hospital
Taian, Shandong, China
People's Liberation Army The General Hospital of Western Theater Command
Chengdu, Sichuan, China